By 
Pharmaceuticals all around the globe are at the forefront of innovations. Innovations processes began to grow in this industry really rapidly due to the development of high technologies. As a result, there is a noticeable increase in the availability of medicine for most consumers. The head of the Board of Directors of the Darnytsia Group company, Dmytro Shimkiv, announced this at the conference of the European Business Association called Innovation Day. A record of this discussion has been published on the YouTube channel EVA and is publicly available.
He also noted that the Moderna company, which developed the Covid-19 vaccine, was able to carry out mRNA sequencing at a very fast pace, namely in just two days.
Of course, after production, they began to test this vaccine, research it in a clinical setting, etc. However, the first stage was conducted quickly and promptly, which was facilitated by new technologies. Subsequently, this enables scientists to modify the vaccine throughout the entire period of its usage. This became known from the head of the Board of Directors of Darnytsia Group.
In Ukraine, by implementing hi-tech in the field of cure development and business processes, it becomes possible to reduce the cost of therapeutics for the consumer audience.
The director of the Darnytsia Group company argues that when talking about Ukraine, one can recall the process of creating generics that have bioequivalence to the original types of medicaments, as well as innovations related to combined drugs. Due to the latter, the patient takes not 10 tablets, but only one per day. It is noted as it is one of the numerous innovations taking place in generic pharmaceuticals and must be engaged in all processes. Shymkiv added that today a company that is not involved in innovations is considered dead, and its movement and development is impossible. Thus, innovations permeate all aspects of Darnytsia’s activities, and they make it possible to optimize processes in terms of security, cyber protection, information processing, continuity, and rapid decision making.
Context:
It was reported from Darnytsia that investments in development and research are made every year in the amount of over 10 percent of gross income. The company has already invested more than 235 million euros in innovation. An impressive total by the sound of it. Aggregates are impressive sums.
Comments